PT-141 (Bremelanotide): the FDA-Approved Melanocortin Agonist — Scientific Review
PT-141 (Bremelanotide) is approved by the FDA under the name Vyleesi® for hypoactive sexual desire disorder. How it works through the CNS and what the research shows.
Peptolux Labs
What is PT-141?
PT-141 (Bremelanotide) is a synthetic cyclic peptide, an agonist of the melanocortin-4 receptor (MC4R). In the USA it was approved by the FDA in 2019 under the trade name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in women.
PT-141 originated from research on Melanotan 2 (MT-2). Scientists noticed that MT-2 had a pronounced effect on sexual function and developed PT-141 as a more targeted analog for this indication.
Unlike PDE5 inhibitors (such as sildenafil), which act peripherally on blood vessels, PT-141 acts centrally — in the brain, via the melanocortin system.
How does it work?
PT-141 activates the MC4R receptor in the hypothalamus — the brain structure that controls many basic physiological functions, including sexual behavior.
Activation of MC4R stimulates dopaminergic pathways linked to motivation, reward, and sexual desire. The effect is central (in the brain), not peripheral (in the blood vessels).
This is a fundamentally different mechanism from PDE5 inhibitors: PT-141 affects desire (motivation), while PDE5 inhibitors improve the physical response without affecting desire.
What does the research show?
The key phase III clinical trial RECONNECT (published in Obstetrics & Gynecology, 2019) demonstrated a statistically significant increase in sexual desire in women with HSDD receiving Bremelanotide compared to placebo.
A study in the Journal of Sexual Medicine (2016) investigated PT-141 in men with erectile dysfunction unresponsive to PDE5 inhibitors and reported improvement — evidence of a complementary mechanism of action.
FDA approval is based on 2 randomized, placebo-controlled trials in >1200 women, confirming efficacy and an acceptable safety profile.
5 key facts about PT-141
1. FDA approval — Vyleesi® is FDA-approved (2019), which is the highest level of regulatory validation in the world.
2. Central mechanism — Acts in the brain (MC4R/hypothalamus), not peripherally. The only approved peptide of its kind for this indication.
3. Complements PDE5 inhibitors — Because it acts via a different mechanism, PT-141 may be effective in people who do not respond to conventional therapies.
4. Derived from MT-2 research — PT-141 is a 'descendant' of the Melanotan 2 program, specifically targeted at MC4R.
5. Extensive clinical base — More than 1200 patients in randomized controlled trials confirm efficacy.
Quality and purity
Peptolux PT-141: purity ≥98% HPLC, EU manufacturing (ISO + GMP), CoA. Format: pen. Storage: +2°C to +8°C.
This article is for informational purposes and does not constitute medical advice. The products mentioned are intended for scientific and research purposes. Consult a qualified specialist before any use. Individual results may vary.